Quantum-Si combines Time Domain Sequencing™ and Semiconductor Chip Technology to Advance Drug Discovery and Diagnostics and Accelerate Scientific Breakthroughs, Helping People to Live Healthier and Longer Lives Company Appoints Life Science Veteran Grace Johnston, PhD, as Chief Commercial Officer Key Takeaways: The accessibility gained when using Platinum™ is expected to transform science and understanding of the […]

GUILFORD, Conn.–(BUSINESS WIRE)– Nov. 07, 2022 — Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), a life sciences company commercializing the first next-generation, single-molecule protein sequencing platform, today announced financial results for the third quarter ending September 30, 2022. Recent Highlights Appointed Jeff Hawkins as Chief Executive Officer and director to the Board. Announced […]

GUILFORD, Conn.–(BUSINESS WIRE)– Nov. 03, 2022–Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), a life sciences company commercializing the first-next generation single-molecule protein sequencing platform, today announced that it will be participating in the 16th Annual Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum taking place at the Westin New York Grand Central, […]

GUILFORD, Conn.–(BUSINESS WIRE)– Oct. 17, 2022–Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), a life sciences company commercializing the first next-generation single-molecule protein sequencing platform, today announced that it will report financial results for the third quarter 2022 after market close on Monday, November 7, 2022. Company management will host a conference call to discuss […]

Semiconductor Chip and Time Domain Sequencing™ Technology Will Advance Drug Discovery and Diagnostics, Enabling People to Live Healthier and Longer Lives Key Takeaways: Next-generation single-molecule protein sequencing technology is poised to transform the science and research community’s understanding of the proteome by unlocking unprecedented insights about the human body — just as the advent of […]

 Veteran Life Sciences Executive to Oversee Commercial Launch of Next-Generation Single-Molecule Protein Sequencing Platform GUILFORD, Conn.–(BUSINESS WIRE)–Oct. 4, 2022– Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), a life sciences company commercializing the first next-generation single-molecule protein sequencing platform, today announced the appointment of Jeff Hawkins as Chief Executive Officer. Mr. Hawkins will succeed […]

GUILFORD, Conn.–(BUSINESS WIRE)–Aug. 26, 2022 — Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), a life sciences company commercializing the first-next generation single-molecule protein sequencing platform, today announced that it will be participating in the Morgan Stanley 20th Annual Global Healthcare Conference taking place at the Sheraton New York, NY, on September 12-14, 2022. […]

GUILFORD, Conn.–(BUSINESS WIRE)– Aug. 08, 2022 — Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), a life sciences company commercializing the first next-generation, single-molecule protein sequencing platform, today announced financial results for the second quarter ending June 30, 2022. Recent Business Highlights Successfully demonstrated the recognition of 15 out of 20 amino acids, representing a […]

GUILFORD, Conn.–(BUSINESS WIRE)– Jul. 18, 2022–Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), a life sciences company commercializing the first next generation single molecule protein sequencing, today announced that it will report financial results for the second quarter 2022 after market close on Monday, August 8, 2022. Company management will host a conference call […]

First of its kind life sciences company continues focus on commercial launch of next-generation protein sequencing platform GUILFORD, Conn.–(BUSINESS WIRE)– June 22, 2022–Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), a life sciences company commercializing single molecule protein sequencing, is set to join the broad-market Russell 2000® Index at the conclusion of the 2022 Russell indexes […]